Phase 3, 914 patients with untreated HER2+ advanced gastroesophageal adenocarcinoma: median PFS 12.4 months with zanidatamab-chemo with or without tislelizumab vs 8.1 with trastuzumab-chemo (HR 0.63, 0.65). At interim analysis, OS was longer only with tislelizumab added.
RCTn = 914
Shitara et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer